ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO Endorses Guideline for Molecular Testing

October 17, 2014

In Brief: Mueller, Rosenberg Head AACR; Elion, Schein Presidents Elect; PHS Offers epidemiology Training

May 7, 1982

Book Review: In Memoir Written to Avoid Doing Time, Disgraced Exec Reflects on BMS Heyday

July 6, 2012

In Brief: Cancer Act Renewal Nears, Appropriations Bills Lag; Interim Funding Likely For ’83 Fiscal Year

September 24, 1982

NCI Marmoset Colony Available For Research

February 11, 1983

Wender Named ACS Chief Cancer Control Officer

August 9, 2013